Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients

Documenti analoghi

• Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer
  di: Mike Wenzel, et al.
  Pubblicazione: (2024)
• Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
  di: Chris H.‐M. Wong, et al.
  Pubblicazione: (2024)
• Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
  di: Michal Jirásko, et al.
  Pubblicazione: (2024)
• Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions
  di: Yitong Weng, et al.
  Pubblicazione: (2025)
• Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
  di: Fabian Falkenbach, et al.
  Pubblicazione: (2024)